Liu Yuqing, Piao Jingyu, He Jiqian, Su Zhuoxuan, Luo Zhizhong, Luo Duosheng
Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine, Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou Guangdong China.
Food Sci Nutr. 2024 Sep 14;12(11):8939-8955. doi: 10.1002/fsn3.4466. eCollection 2024 Nov.
Atherosclerosis (AS) is the pathologic basis of many cardiovascular diseases (CVDs). Hydroxysafflor yellow A (HSYA) is a valuable natural food pigment that has been reported to have significant health-promoting abilities. However, the anti-AS efficacy and mechanisms of HSYA have not yet been characterized. Here, we found that treatment of apolipoprotein A (ApoE) knockout (ApoE) mice with HSYA markedly ameliorated atherosclerosis evidenced by decreased levels of lipids, sphingosine-1-phosphate (S1P), inflammatory factors, oxidative stress, vascular endothelial permeability, and endothelial damage. Moreover, mechanistic studies revealed that HSYA treatment downregulated the expression of aortic sphingosine kinase 1 (SphK1), sphingosine-1-phosphate receptor 3 (S1PR3), Ras homolog family member A (RhoA), Rho-associated coiled-coil containing protein kinase (ROCK), and filamentous actin (F-actin). The results of administration with HSYA reversed the effects of SphK1 agonist and S1PR3 agonist on oxidized low-density lipoprotein (ox-LDL)-induced vascular endothelial cell migration ability and F-actin expression, and decreased RhoA/ROCK protein expression further confirmed the conclusion that HSYA reduced vascular endothelial permeability by modulating the SphK1/S1P/S1PR3/RhoA/ROCK signaling pathway, thereby exerting anti-atherosclerotic effects. Overall, this study indicated that HSYA might be a therapeutic candidate for the treatment of AS.
动脉粥样硬化(AS)是许多心血管疾病(CVD)的病理基础。羟基红花黄色素A(HSYA)是一种珍贵的天然食用色素,据报道具有显著的促进健康的能力。然而,HSYA的抗AS功效和机制尚未明确。在此,我们发现用HSYA处理载脂蛋白A(ApoE)基因敲除(ApoE)小鼠可显著改善动脉粥样硬化,表现为脂质、鞘氨醇-1-磷酸(S1P)、炎症因子、氧化应激、血管内皮通透性和内皮损伤水平损伤水平降低。此外,机制研究表明,HSYA处理可下调主动脉鞘氨醇激酶1(SphK1)、鞘氨醇-1-磷酸受体3(S1PR3)、Ras同源家族成员A(RhoA)、Rho相关卷曲螺旋蛋白激酶(ROCK)和丝状肌动蛋白(F-肌动蛋白)的表达。给予HSYA的结果逆转了SphK1激动剂和S1PR3激动剂对氧化低密度脂蛋白(ox-LDL)诱导的血管内皮细胞迁移能力和F-肌动蛋白表达的影响,RhoA/ROCK蛋白表达降低进一步证实了HSYA通过调节SphK1/S1P/S1PR3/RhoA/ROCK信号通路降低血管内皮通透性,从而发挥抗动脉粥样硬化作用的结论。总体而言,本研究表明HSYA可能是治疗AS的候选药物。